|
| At this year's Eurotox in Copenhagen, we were delighted to have experts from Lundbeck and Unilever joining us to discuss the latest advancements in skin sensitization testing. During the event, we also unveiled exciting GARD® updates from collaborative projects, including those of Cargill and ExxonMobil Biomedical Sciences. |
|
|
|
 |
In collaboration with L'Oréal’s scientific team, SenzaGen has co-authored a peer-reviewed article in Toxics (MDPI). The paper highlights the effectiveness of the GARD®skin Dose-Response assay in Quantitative Risk Assessment.
The study, which involved 30 chemicals and a composite potency model, demonstrates the assay’s ability to predict a Point-of-Departure (PoD) for potential skin sensitizers, showing concordance with NESIL values derived from LLNA and Human data. This is a key advancement in enhancing risk assessment strategies for chemical safety.
Explore the latest insights |
|
|
 |
We are excited to announce that another leading chemical company has adopted the GARD®skin Dose-Response assay to determine safe dose levels for specialty chemicals in their product development, as an alternative to animal testing.
Discover how the assay enhances risk assessment
|
|
|
 |
Our collaboration with RIFM is set to expand to further develop the GARD®skin Dose-Response method for identifying photoallergens. This initiative aims to deliver quantitative insights into skin sensitization, helping to differentiate photoallergens from photoirritants, which is crucial for safety in cosmetics and chemicals.
Stay tuned for further updates on this important initiative!
|
|
|
 |
| To meet the increasing demand for our innovative GARD® assay portfolio for skin and respiratory sensitization, we are expanding our partner network. We are excited to welcome IIVS as our latest partner, sharing our dedication to top-tier product quality and supporting our mission to move away from animal testing. |
|
|
🌎 Conference: ASCCT Annual Meeting 2024 | North Carolina, USA | October 28-30
|
|
|
|
